Sotrovimab Expanded Access Treatment Protocol (COVID-19)
NCT05235347 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-11-10
Summary
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
Conditions
- Covid19
Interventions
- BIOLOGICAL
-
Sotrovimab
500mg IV
Sponsors & Collaborators
-
Vir Biotechnology, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Expanded Access Remdesivir (RDV; GS-5734™)
NCT04302766 ·Status: NO_LONGER_AVAILABLE
-
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
NCT04949386 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of S-892216 in Participants With COVID-19
NCT06928051 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
NCT04632381 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
NCT04622332 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
NCT05373433 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
NCT04323761 ·Status: APPROVED_FOR_MARKETING
-
Efficacy of Tocilizumab on Patients With COVID-19
NCT04356937 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
NCT04705597 ·Status: TERMINATED ·Phase: PHASE2
-
Defibrotide for the Treatment of Severe COVID-19
NCT04652115 ·Status: RECRUITING ·Phase: PHASE2
-
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
NCT05124210 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
NCT04380961 ·Status: COMPLETED ·Phase: PHASE2
-
Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )
NCT05144178 ·Status: UNKNOWN
-
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
NCT05077332 ·Status: COMPLETED ·Phase: PHASE2
-
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
NCT04617535 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access to Zofin for Patients With COVID-19
NCT04657406 ·Status: AVAILABLE
-
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
NCT05047601 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
NCT04720378 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
NCT05897541 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486 ·Status: NO_LONGER_AVAILABLE
-
COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
NCT05302947 ·Status: COMPLETED
-
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
NCT05736861 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
NCT05369676 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
NCT05785390 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19
NCT05365321 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2